Sanofi buys haemophilia specialist for $11.6 bn 1:46pm GMT - 01:31 
Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion. As Silvia Antonioli reports, the French healthcare group says the deal will boost earnings and strengthen its presence in treatments for rare diseases.   
Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion. As Silvia Antonioli reports, the French healthcare group says the deal will boost earnings and strengthen its presence in treatments for rare diseases.  //reut.rs/2DxBseA